PTX Media related, page-793

Yes I am looking forward to the Boston Summit. It goes to show that we are highly regarded and respected to be invited to present at the Summit.

With a low market cap and the exposure we will get at the Summit to both other biotech companies and fund managers and venture capitalists that is a first time one would expect will certainly put us on the map.

Looking back over the last year we made seven presentations, market updates on the ASX but I doubt whether it made any traction with international investors. One only has to look at the annual report 2021 and compare it to the annual report of 2022 and one will notice that the top 20 have decreased in number by about 4 million, the register for the top 20 is very open dropping from 17% down to 16%. I invest in a wide range of companies and this has not attracted long-term institutions despite brilliant presentations.The reasons could be many.I It is difficult for the SP to go forward with a decrease in top 20 shareholders.

Looking at the annual report presentation for 2021 it was called “a transformational year “ and I believe the annual report for 2022 is even better as we have marched forward greatly.
One statement that was made in the annual report of 2021 “achievements becoming reflected in company evaluation $.28 MC $180m November 2021.”Since then the SP has gone back to 17 1/2 cents and I would say reflects market conditions not company achievements. Let’s see if the new potential investors will contemplate buying PTX from the summit will agree the reverse of PTX statement “achievements are not reflected in the current valuation.”